SGLT2 Inhibitors Do Not Reduce Renal Cyst Size in ADPKD
SGLT2 inhibitors are not indicated for reducing renal cyst size in ADPKD patients. While these agents may offer renoprotective benefits for slowing eGFR decline in ADPKD when used alongside standard therapies, current evidence shows they do not meaningfully reduce total kidney volume or cyst size—and may actually increase kidney volume in some cases.
Evidence on Cyst Size and Kidney Volume
The available research specifically examining SGLT2 inhibitors in ADPKD populations demonstrates:
Kidney volume increases with SGLT2i treatment: A retrospective study of 7 ADPKD patients treated with dapagliflozin showed that annual height-corrected total kidney volume increased in all patients, regardless of whether they received concurrent tolvaptan 1.
No reduction in total kidney volume: A systematic review and meta-analysis of 451 ADPKD patients failed to demonstrate any statistically significant difference in total kidney volume change with SGLT2 inhibitor therapy (mean difference: -31.31 mL per year; 95% CI: -184.00 to 121.37) 2.
Potential Renoprotective Effects (Not Related to Cyst Size)
Despite the lack of effect on cyst burden, SGLT2 inhibitors may still offer kidney function benefits:
The eGFR slope improved in 5 of 6 ADPKD patients after dapagliflozin initiation, but only when used concomitantly with RAS inhibitors 1. The one patient without a RAS inhibitor showed no improvement.
The meta-analysis showed a modest attenuation in eGFR decline rate during the first year (mean difference: 0.65 mL/min/1.73 m² per year; 95% CI: 0.05-1.26) compared to pre-SGLT2i slopes 2.
However, when compared directly to non-SGLT2i therapy, no statistically significant difference in first-year eGFR slope change was demonstrated (mean difference: 2.12 mL/min/1.73 m² per year; 95% CI: -8.13 to 12.38) 2.
Clinical Context and Guideline Perspective
The 2025 KDIGO ADPKD guideline does not recommend SGLT2 inhibitors for ADPKD-specific management 3. The guideline focuses on tolvaptan as the cornerstone therapy for patients at risk of rapid progression, with evidence showing tolvaptan reduces total kidney volume growth by 2.7% (95% CI: -3.3% to -2.1%) 3.
For ADPKD patients who also have:
Diabetes and eGFR ≥20 mL/min/1.73 m²: SGLT2 inhibitors are strongly recommended for cardiorenal protection based on general CKD guidelines 4, 5, but this indication is for preventing CKD progression and cardiovascular events—not for ADPKD-specific outcomes like cyst reduction.
Non-diabetic CKD with albuminuria: Recent guidelines support SGLT2i use for renoprotection 6, but again, this is for general CKD benefits, not ADPKD cyst management.
Important Caveats
ADPKD was an exclusion criterion in pivotal SGLT2i trials (DAPA-CKD, EMPA-KIDNEY) 1, 2, so evidence is limited to small observational studies with substantial heterogeneity.
Safety concerns remain theoretical but include the possibility of accelerated cyst growth given the observed kidney volume increases 1.
An ongoing feasibility trial (empagliflozin in ADPKD) is assessing safety and tolerability but has not yet reported efficacy outcomes 7.
Clinical Algorithm for ADPKD Patients
For ADPKD-specific disease modification:
- Use tolvaptan if the patient meets criteria for rapid progression risk 3
- SGLT2 inhibitors should not be prescribed with the expectation of reducing cyst size or kidney volume
For concurrent diabetes/CKD requiring renoprotection:
- Initiate SGLT2i (dapagliflozin 10 mg or empagliflozin 10-25 mg) if eGFR ≥20-25 mL/min/1.73 m² 4, 8
- Must be combined with RAS inhibitor for any potential kidney function benefit in ADPKD 1
- Monitor for kidney volume progression and counsel patients that cyst growth may continue or accelerate
- Continue SGLT2i even if eGFR falls below initiation threshold unless not tolerated 4, 5
Bottom line: If the goal is to reduce renal cyst size or total kidney volume in ADPKD, SGLT2 inhibitors are not the appropriate therapy. If the goal is cardiorenal protection in an ADPKD patient with diabetes or proteinuric CKD, SGLT2 inhibitors may be used for their general CKD benefits, but expectations regarding cyst reduction should be explicitly managed.